The affected lots were distributed from June 2022 to October 2022.
Additional information can be found on the FDA website.
Ascend Laboratories is advising pharmacies, wholesalers, and distributors with existing supplies of the affected lots to stop distributing and using them and immediately isolate the product.
FDA Link:
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ascend-laboratories-llc-issues-voluntary-nationwide-recall-dabigatran-etexilate-capsules-usp-75-mg
The above information is supplied as study support and is not intend to be used or repurposed as medical advice. Always follow the advice, guidelines and protocols of your provider or supervising agency.
